Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1952 2
1956 1
1995 1
1996 1
1997 1
1999 4
2001 6
2002 2
2003 4
2004 4
2005 1
2006 2
2007 2
2008 5
2009 7
2010 12
2011 4
2012 8
2013 8
2014 2
2015 2
2016 3
2017 2
2019 1
2021 1
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.
Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD; CSP 468 Study Group. Weaver FM, et al. JAMA. 2009 Jan 7;301(1):63-73. doi: 10.1001/jama.2008.929. JAMA. 2009. PMID: 19126811 Free PMC article. Clinical Trial.
Movement disorders.
Colcher A. Colcher A. Clin Podiatr Med Surg. 1999 Jan;16(1):127-39. Clin Podiatr Med Surg. 1999. PMID: 9929775 Review.
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM; Huntington Study Group/ARC-HD Investigators and Coordinators. Frank S, et al. CNS Drugs. 2022 Nov;36(11):1207-1216. doi: 10.1007/s40263-022-00956-8. Epub 2022 Oct 15. CNS Drugs. 2022. PMID: 36242718 Free PMC article. Clinical Trial.
Other Parkinson syndromes.
Colcher A, Simuni T. Colcher A, et al. Neurol Clin. 2001 Aug;19(3):629-49, vii. doi: 10.1016/s0733-8619(05)70038-4. Neurol Clin. 2001. PMID: 11532647 Review.
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.
McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators. McGarry A, et al. Among authors: colcher a. Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2. Neurology. 2017. PMID: 27913695 Free PMC article. Clinical Trial.
Clinical manifestations of Parkinson's disease.
Colcher A, Simuni T. Colcher A, et al. Med Clin North Am. 1999 Mar;83(2):327-47. doi: 10.1016/s0025-7125(05)70107-3. Med Clin North Am. 1999. PMID: 10093581 Free article. Review.
Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.
Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr; North American Parkinson's and Melanoma Survey Investigators. Bertoni JM, et al. Arch Neurol. 2010 Mar;67(3):347-52. doi: 10.1001/archneurol.2010.1. Arch Neurol. 2010. PMID: 20212233
82 results